Hexarelin

Hexarelin, also called examorelin, is a synthetic growth-hormone-releasing peptide. Bodybuilding and biohacking discussions focus on recovery, sleep and physique changes, with a tradeoff: reports also describe pronounced fatigue, restless nights and hormone-related concerns. A stronger hormone pulse does not establish better muscle or fat-loss results.

It prompts hormone release. This six-amino-acid peptide stimulates the body's release of growth hormone (GH). It is not injected HGH itself. Community descriptions call it a strong GHRP; potency rankings are discussion shorthand, not a reliable ranking of results. Imbimbo et al. 1994 — human GH-response dose study (Official context · Accessed 2026-09-30)

Form and route matter. The practical discussion centers on subcutaneous injections, meaning under the skin. Historical oral, intranasal and IV research exists, but those forms do not share an interchangeable amount or timing. CJC with DAC is also different from the no-DAC/Mod GRF pairing. Rahim et al. 1998 — long-term Hexarelin therapy (Official context · Accessed 2026-09-30)

Source context — Imbimbo et al. 1994 — human GH-response dose study: Abstract only, truncated at 250 words. Measures GH after dosing, not parent-Hexarelin clearance, community felt onset or SC effectiveness.

Source context — Rahim et al. 1998 — long-term Hexarelin therapy: Abstract only; study population indexed as aged, including men/women. Research schedule is not a bodybuilding cycle. No significant body-composition change is not proof every community user has no benefit.

Recovery and physique. Less training soreness, fuller muscles and easier fat loss are recurring goals in the preserved discussion. A Reddit follow-up describes a leaner look and modest strength improvement, but supplies no measurements that isolate Hexarelin from training or other factors. Hexarelin discussion: guide claims and individual follow-ups (Community discussion · Accessed 2026-09-30)

Sleep is a mixed benefit. Some accounts favor the relaxed feeling; others describe daytime exhaustion or a heavy body with an alert, anxious mind at bedtime. Feeling sleepy is not the same as sleeping well or recovering better. Hexarelin: severe lethargy and a one-hour half-life reply (Community discussion · Accessed 2026-09-30) · Hexarelin discussion: guide claims and individual follow-ups (Community discussion · Accessed 2026-09-30)

Relaxation can become a burden. Elvia1023 enjoyed the relaxed feeling yet later described difficulty working from fatigue. His earlier good-sleep and tingling posts preceded Hexarelin, so they cannot be treated as Hexarelin outcomes. CJC-1295 with DAC and Hexarelin Log (Personal report · Accessed 2026-09-30)

Little felt effect is not an invitation to escalate. lifting211 says little was felt at 100/200 mcg, yet also reports insomnia; at a reported 600 mcg, hunger became extreme. CJC-DAC co-use and the poster's doubts about vial identity make this an uncertain adverse account, not a higher-dose success. Hexarelin high dosage and other peptides (Personal report · Accessed 2026-09-30)

Source context — Hexarelin discussion: guide claims and individual follow-ups: Guide-like OP includes promotional vendor framing and unsupported superlatives; its schedules are circulated claims. Follow-up comments are separate subjective reports with incomplete route/amount/co-use details. Relative timestamps not converted to publication dates.

Source context — Hexarelin: severe lethargy and a one-hour half-life reply: Single self-report plus forum opinion on a source-review platform. Co-use confounds the fatigue. Reply provides no underlying half-life measurement or route-specific PK reference.

Source context — CJC-1295 with DAC and Hexarelin Log: CJC-DAC and multiple anabolic steroids, later planned additions, unverified products and apparent supplier affiliation. Pre-Hexarelin improvements cannot be credited to Hexarelin; no measured GH in these posts.

Source context — Hexarelin high dosage and other peptides: OP says little was felt at 100/200 mcg but also reports insomnia at those amounts. Possible mislabeling and co-use; no route explicitly stated in inspected text. Extreme amount is an adverse anecdote, not an endorsed range.

SC chart amounts: 50–200 mcg per injection. Preserved charts center on about 100 mcg, with one to three injections daily. They separately list roughly 200–600 mcg/day in multi-pulse schedules and upper reports of 200–300 mcg per injection. These are different patterns, not a progression or a validated target.

Lower amounts also appear. Elvia1023 actually logged 33 mcg injections, later about 50 mcg, alongside CJC-DAC and anabolic steroids. The lower amount did not make the account free of fatigue. CJC-1295 with DAC and Hexarelin Log (Personal report · Accessed 2026-09-30)

Paired amounts are separate components. A Reddit OP proposed 100 mcg Hexarelin plus 100 mcg MOD GRF-1, two to three times daily; it was a plan, not a result. Other preserved pairing charts list 100–200 mcg Hexarelin with about 100 mcg Mod GRF, sometimes 100–200 mcg of the GHRH component. Hexarelin? — a planned MOD GRF-1 pairing (Community discussion · Accessed 2026-09-30)

Source context — CJC-1295 with DAC and Hexarelin Log: CJC-DAC and multiple anabolic steroids, later planned additions, unverified products and apparent supplier affiliation. Pre-Hexarelin improvements cannot be credited to Hexarelin; no measured GH in these posts.

Source context — Hexarelin? — a planned MOD GRF-1 pairing: A proposed schedule/question, not a completed experiment or evidence that weekends prevent attenuation. Route not explicit in OP; kept separate from the preserved SC chart.

Minutes for sensations; days for fatigue. In the 2016 forum thread, Progress reports warmth around five minutes and hunger around twenty minutes after a labeled 50 mcg injection. PNE FC describes marked lethargy from day two. These are individual observations, not a standard onset. Hexarelin: amounts, hunger and food-timing disagreement (Community discussion · Accessed 2026-09-30) · Hexarelin: severe lethargy and a one-hour half-life reply (Community discussion · Accessed 2026-09-30)

Recovery is a slower claim. The preserved account places sleep or recovery changes in the first one to two weeks when noticed. It provides no controlled comparison or dependable date for muscle gain, fat loss or benefit.

Brief sensations and longer sleep effects. Elvia1023 reports being spaced out for a few minutes, then later sleeping for several hours after about 50 mcg. A Reddit user describes an energized, racing feeling that eventually settles, without a measured interval. CJC-1295 with DAC and Hexarelin Log (Personal report · Accessed 2026-09-30) · Hexarelin discussion: guide claims and individual follow-ups (Community discussion · Accessed 2026-09-30)

One to two hours is circulated pulse lore. That SC GH-elevation window is in the preserved community account, not a measured Hexarelin benefit window. Neither a short pulse nor a long nap tells us how long recovery or physique effects last, including after stopping.

About one hour is repeated. An Eroids reply says the half-life seems to be about an hour, without citing a measurement. It then argues for more frequent dosing; that conclusion is the poster's opinion. This does not establish how quickly injected Hexarelin clears from human blood. Hexarelin: severe lethargy and a one-hour half-life reply (Community discussion · Accessed 2026-09-30)

Human GH response is not peptide clearance. Imbimbo's IV study used 0.5, 1 and 2 mcg/kg. GH peaked around thirty minutes and returned to baseline within 240 minutes; about 55 minutes described released GH, not parent Hexarelin. Imbimbo et al. 1994 — human GH-response dose study (Official context · Accessed 2026-09-30)

Animal parent half-lives stay animal. Rat IV parent-peptide half-life was 75.9 ± 9.3 minutes; dog IV terminal half-life was 120 minutes. Neither supplies a measured human SC value. Roumi et al. 2000 — Hexarelin disposition in rats (Animal context · Accessed 2026-09-30) · Roumi et al. 1995 — Hexarelin pharmacokinetics in dogs (Animal context · Accessed 2026-09-30)

Source context — Hexarelin: amounts, hunger and food-timing disagreement: Commercial forum. Mixed first-person reports, copied chart and secondhand unseen bloodwork; no supplied lab results. Lactation is a symptom report, not confirmation of a prolactin value.

Source context — Hexarelin: severe lethargy and a one-hour half-life reply: Single self-report plus forum opinion on a source-review platform. Co-use confounds the fatigue. Reply provides no underlying half-life measurement or route-specific PK reference.

Source context — CJC-1295 with DAC and Hexarelin Log: CJC-DAC and multiple anabolic steroids, later planned additions, unverified products and apparent supplier affiliation. Pre-Hexarelin improvements cannot be credited to Hexarelin; no measured GH in these posts.

Source context — Hexarelin discussion: guide claims and individual follow-ups: Guide-like OP includes promotional vendor framing and unsupported superlatives; its schedules are circulated claims. Follow-up comments are separate subjective reports with incomplete route/amount/co-use details. Relative timestamps not converted to publication dates.

Source context — Imbimbo et al. 1994 — human GH-response dose study: Abstract only, truncated at 250 words. Measures GH after dosing, not parent-Hexarelin clearance, community felt onset or SC effectiveness.

Source context — Roumi et al. 2000 — Hexarelin disposition in rats: Animal abstract only. Rat route-specific pharmacokinetics cannot become a measured human SC half-life.

Source context — Roumi et al. 1995 — Hexarelin pharmacokinetics in dogs: Animal abstract only; species, route and terminal endpoint remain distinct from human clearance or felt duration.

Short blocks have competing calendars. The Reddit guide circulates two to four weeks on and the same time off. Another commenter describes four weeks on/four off. Preserved charts also include four to eight weeks, or eight to twelve weeks followed by multi-week breaks, sometimes at least four weeks or equal time off. Hexarelin discussion: guide claims and individual follow-ups (Community discussion · Accessed 2026-09-30) · GHRH/GHRP cycling question (Community discussion · Accessed 2026-09-30)

Intermittent use is a proposal, not protection. Five days on/two off appears in the MOD GRF OP; training-days-only use and fewer daily pulses also circulate. None establishes prevention of blunting. Reports of fading sensation around weeks four to six and stronger sensations after a break do not measure GH responsiveness. Hexarelin? — a planned MOD GRF-1 pairing (Community discussion · Accessed 2026-09-30)

A longer study did not establish physique gains. Rahim's 16-week study used 1.5 mcg/kg SC twice daily. GH response attenuated by weeks four and sixteen, recovering after four weeks off. IGF-I, body fat, lean mass and bone density did not significantly change; one collagen-formation marker rose. This supports reversible attenuation, not permanent receptor burnout or an optimal cycle. Rahim et al. 1998 — long-term Hexarelin therapy (Official context · Accessed 2026-09-30)

Source context — Hexarelin discussion: guide claims and individual follow-ups: Guide-like OP includes promotional vendor framing and unsupported superlatives; its schedules are circulated claims. Follow-up comments are separate subjective reports with incomplete route/amount/co-use details. Relative timestamps not converted to publication dates.

Source context — GHRH/GHRP cycling question: Confounded stacks and unsupported receptor-burnout language. Separate symptoms cannot be assigned solely to Hexarelin. Dates visible in search cache; opened body uses relative timestamps.

Source context — Hexarelin? — a planned MOD GRF-1 pairing: A proposed schedule/question, not a completed experiment or evidence that weekends prevent attenuation. Route not explicit in OP; kept separate from the preserved SC chart.

Source context — Rahim et al. 1998 — long-term Hexarelin therapy: Abstract only; study population indexed as aged, including men/women. Research schedule is not a bodybuilding cycle. No significant body-composition change is not proof every community user has no benefit.

CJC-1295 no-DAC (Mod GRF 1-29) + hexarelin: Classic GHRH + GHRP dual-pulse stack; community often pairs ~100 mcg Mod GRF with ~100–200 mcg hexarelin, 1–3×/day same timing. [community]

Sermorelin + hexarelin: Older GHRH fragment pairing still discussed as a dual-path pulse stack. [community]

Form and route matter. The practical discussion centers on subcutaneous injections, meaning under the skin. Historical oral, intranasal and IV research exists, but those forms do not share an interchangeable amount or timing. CJC with DAC is also different from the no-DAC/Mod GRF pairing. Rahim et al. 1998 — long-term Hexarelin therapy (Official context · Accessed 2026-09-30)

Lower amounts also appear. Elvia1023 actually logged 33 mcg injections, later about 50 mcg, alongside CJC-DAC and anabolic steroids. The lower amount did not make the account free of fatigue. CJC-1295 with DAC and Hexarelin Log (Personal report · Accessed 2026-09-30)

Stack claims complicate comparisons. One brief Hexarelin/ipamorelin testimonial favors it over CJC/ipamorelin but mentions more side effects without detail. Rotation, additional GHRPs, MK-677 and BPC/TB combinations appear in discussion; they increase attribution uncertainty rather than prove synergy or safer use. Anyone run Hexarelin + Ipamorelin for strength cycles? (Community discussion · Accessed 2026-09-30)

Hormones beyond GH. Human IV research found prolactin and cortisol increases. Forum libido, mood, lactation and wired-tired concerns therefore deserve attention, but symptoms alone do not identify a hormone level. Adding ipamorelin is not established to cancel Hexarelin's effects. Massoud et al. 1996 — GH, cortisol and prolactin response (Official context · Accessed 2026-09-30) · Hexarelin: amounts, hunger and food-timing disagreement (Community discussion · Accessed 2026-09-30) · Anyone run Hexarelin + Ipamorelin for strength cycles? (Community discussion · Accessed 2026-09-30)

Rotate / switch to Ipamorelin: Common when users want longer runs with less cortisol/prolactin or when hexarelin desensitization dominates. [community]

BPC-157 / TB-500 (“Wolverine”) + GH axis: Occasional heal + secretagogue lifestyle stacks—outcomes confounded; no requirement to combine. [community]

MK-677 (ibutamoren) overlap caution: Both hit GH secretagogue pathways; some advanced logs layer oral MK with injectables, others avoid stacking two strong GHS approaches due to side-effect load (hunger, water, insulin sensitivity talk)—not a hexarelin-specific trial protocol. [community]

Source context — Rahim et al. 1998 — long-term Hexarelin therapy: Abstract only; study population indexed as aged, including men/women. Research schedule is not a bodybuilding cycle. No significant body-composition change is not proof every community user has no benefit.

Source context — CJC-1295 with DAC and Hexarelin Log: CJC-DAC and multiple anabolic steroids, later planned additions, unverified products and apparent supplier affiliation. Pre-Hexarelin improvements cannot be credited to Hexarelin; no measured GH in these posts.

Source context — Anyone run Hexarelin + Ipamorelin for strength cycles?: Brief vague testimonial does not supply measured strength, amount, isolated outcome or side-effect description. Ipamorelin-as-buffer and most-lifters assertions are unsupported by this thread.

Source context — Massoud et al. 1996 — GH, cortisol and prolactin response: Primary abstract only; acute IV design. Does not translate to a fixed flat SC dose ceiling or demonstrate that adding another peptide prevents adverse effects.

Source context — Hexarelin: amounts, hunger and food-timing disagreement: Commercial forum. Mixed first-person reports, copied chart and secondhand unseen bloodwork; no supplied lab results. Lactation is a symptom report, not confirmation of a prolactin value.

Hormones beyond GH. Human IV research found prolactin and cortisol increases. Forum libido, mood, lactation and wired-tired concerns therefore deserve attention, but symptoms alone do not identify a hormone level. Adding ipamorelin is not established to cancel Hexarelin's effects. Massoud et al. 1996 — GH, cortisol and prolactin response (Official context · Accessed 2026-09-30) · Hexarelin: amounts, hunger and food-timing disagreement (Community discussion · Accessed 2026-09-30) · Anyone run Hexarelin + Ipamorelin for strength cycles? (Community discussion · Accessed 2026-09-30)

Fatigue, swelling and uncertain vials. Preserved reports include headache, flushing, injection-site irritation, puffiness, joint tightness and hand tingling. Hunger is sometimes compared with a milder version of GHRP-6, but accounts vary. Glucose/insulin concerns also appear in GH-axis stack talk. Tingling or hunger does not prove purity, dose accuracy or useful GH release.

Sport and heart claims. WADA's 2026 list names examorelin/Hexarelin as prohibited at all times. The cardiac/CD36 research interest does not establish protection for people using bodybuilding stacks. WADA 2026 Prohibited List (Official context · Accessed 2026-09-30) · Agbo et al. 2019 — Hexarelin in a rat heart-failure model (Animal context · Accessed 2026-09-30)

Source context — Massoud et al. 1996 — GH, cortisol and prolactin response: Primary abstract only; acute IV design. Does not translate to a fixed flat SC dose ceiling or demonstrate that adding another peptide prevents adverse effects.

Source context — Hexarelin: amounts, hunger and food-timing disagreement: Commercial forum. Mixed first-person reports, copied chart and secondhand unseen bloodwork; no supplied lab results. Lactation is a symptom report, not confirmation of a prolactin value.

Source context — Anyone run Hexarelin + Ipamorelin for strength cycles?: Brief vague testimonial does not supply measured strength, amount, isolated outcome or side-effect description. Ipamorelin-as-buffer and most-lifters assertions are unsupported by this thread.

Source context — WADA 2026 Prohibited List: Sports anti-doping rule, not a general legal classification or drug-approval finding.

Source context — Agbo et al. 2019 — Hexarelin in a rat heart-failure model: Actual full-text sections inspected; figures and all detailed results not comprehensively reviewed. Animal disease model cannot establish heart protection in gym users.